Inhaled Sobetirome as a novel therapeutic agent in ARDS

• Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a major cause of respiratory failure.
• 200,000 adults and 15,000 children in US are affected with ARDS, with a mortality rate of ~40%. • Treatment options are limited to mechanical ventilation. No FDA approved drugs on the market yet.
• Thyroid hormone (TH) and the thyroid receptor agonist Sobetriome (GC-1) attenuate hyperoxia induced ALI in WT mice.
• IP Status: U.S. provisional patent application 62/641,643
• Innovators: Naftali Kaminski, MD; Patty Lee, MD